# Data Integrity for In Vivo Bioavailability and Bioequivalence Studies - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b

> FDA guidance document: Data Integrity for In Vivo Bioavailability and Bioequivalence Studies. Issue date: April 03, 2024. Get complete insights and analysis.

---

## Details

- Title: Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-04-03
- Comment Close Date: 2024-07-03
- Last Changed: 2024-04-02
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-1245">FDA-2024-D-1245</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application](https://www.globalkeysolutions.net/guidances/guidance-document/bioequivalence-studies-with-pharmacokinetic-endpoints-for-drugs-submitted-under-an-abbreviated-new-drug-application/1da84f16-4374-4eb9-87cd-f13d1d965346)
- [Statistical Approaches to Establishing Bioequivalence](https://www.globalkeysolutions.net/guidances/guidance-document/statistical-approaches-to-establishing-bioequivalence/ecbc1c62-e39f-4980-b654-baa7788c2171)